IM Cannabis Corp

IM Cannabis Corp(IMCC)股票分析

$1.390

+0.063 (+4.51%)收盤時

Loading chart…
最高
1.460
開盤
1.310
成交量加權均價
1.39
成交量
86.02K
市值
6.03M
最低
1.310
成交金額
119.27K
企業價值/稅息折舊攤銷前利潤(TTM)
-0.64

IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.

AI 分析 of IM Cannabis Corp (IMCC)

賣出

IM Cannabis Corp. is not a good buy right now due to its significant financial struggles and negative market sentiment. The stock has dropped 96.89% year-to-date, and the current RSI is at 27.00, indicating it is oversold but still under pressure. Additionally, the company reported a net income loss of CAD 4.36 million in Q2 2026, which raises concerns about its profitability and sustainability.

估值指標

IM Cannabis Corp(IMCC)目前預期本益比為 42.37,5 年平均預期本益比為 -0.62。

預期本益比

高估
5 年均值 P/E
-0.62
目前P/E
42.37
高估
38.52
低估
-39.76

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-6.02
目前EV/EBITDA
-0.64
高估
19.31
低估
-31.35

預期股價營收比

合理
5 年均值 P/S
0.45
目前P/S
0.02
高估
1.20
低估
-0.31

Alphio AI 對 IMCC 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%IMCC

$3.63

情境價格

基

基準

基準 · 50%IMCC

$3.29

情境價格

悲

悲觀

悲觀 · 25%IMCC

$3.15

情境價格

事件時間軸

2026-10-08 (ET)

16:30:00

Selling Stockholders Offer 2.8M Common Shares

2026-09-23 (ET)

09:00:00

IM Cannabis Issues 655,000 Shares at $2 Each

08:00:00

IM Cannabis Signs LOI to Acquire 51% Stake in Space Defense

2026-08-26 (ET)

20:00:00

IM Cannabis Trading Halted, News Pending

2026-06-18 (ET)

08:00:00

IM Cannabis Signs LOI with Slil.com to Sell European Assets

資訊

IMCC 常見問題 —— 由 Alphio AI 解答

IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

IM Cannabis Corp. is not a good buy right now due to its significant financial struggles and negative market sentiment. The stock has dropped 96.89% year-to-date, and the current RSI is at 27.00, indicating it is oversold but still under pressure. Additionally, the company reported a net income loss of CAD 4.36 million in Q2 2026, which raises concerns about its profitability and sustainability.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易